Hostname: page-component-84b7d79bbc-rnpqb Total loading time: 0 Render date: 2024-07-27T19:21:09.856Z Has data issue: false hasContentIssue false
  • English
  • Français

Thymosthenic Agents, A Novel Approach in the Treatment of Schizophrenia

Published online by Cambridge University Press:  06 August 2018

Yves G. Gelders
Yves G. Gelders*
Affiliation:
Clinical R & D Department Psychiatry, Janssen Research Foundation, Beerse
Get access Rights & Permissions [Opens in a new window]

Extract

The pharmacotherapy of psychotic disorders which started in 1952, based on empirical results obtained with chlorpromazine by Delay & Deniker, has revolutionised the treatment of psychiatric diseases of non-organic origin. The discovery of haloperidol by Janssen in 1959 represented further progress in this field, since this was found to be more potent and to have generally less disturbing adverse effects than chlorpromazine. Nevertheless it took several years before dopamine-antagonism was put forward as possible mechanism of action for neuroleptic drugs (Carlsson & Lindqvist, 1963). From the early 1970s, however, the advent of radioligand binding studies provided new tools for studying neurotransmitter receptors in the brain and for investigating the interaction of drugs with various receptors. This technique allowed identification of receptor-binding sites related to pharmacologically defined receptors and receptor subtypes, e.g. α and β-adrenergic receptors. It also led to further subclassification and refined definition of receptors, e.g. dopamine-D1 and -D2, and different pharmacological effects mediated by the receptor subtypes have been identified.

Type
II. From the Perspective of Neurobiology and Pharmacotherapy
Information
The British Journal of Psychiatry , Volume 155 , Issue S5: Schizophrenia as a Systems Disorder: The Relevance of Mediating Processes for Theory and Therapy , July 1989 , pp. 33 - 36
Copyright
Copyright © The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Carlsson, A. & Lindqvist, M. (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Toxicologica et Pharmacologica, 20, 140–144.CrossRefGoogle ScholarPubMed
Ceulemans, D. L. S., Gelders, Y. G., Hoppenbrouwers, M.-L., et al (1985) Effect of serotonin antagonism in schizophrenia: A pilot study with setoperone. Psychopharmacology, 85, 329–332.Google Scholar
Crow, T. J. (1980) Molecular pathology of schizophrenia: More than one disease process? British Medical Journal, 280, 66–68.CrossRefGoogle ScholarPubMed
DeClerck, A. C., Wauquier, A., Van der Ham-Veltman, P. H. M., et al (1987) Increase in slow-wave sleep in humans with the serotonin-S2 antagonist ritanserin (the first exploratory polygraphic sleep study). Current Therapeutic Research, 41, 427–432.Google Scholar
DeLisi, L. E., Neckers, L. M., Weinberger, D. R., et al (1981) Increased whole blood serotonin concentrations in chronic schizophrenic patients. Archives of General Psychiatry, 38, 647–650.Google Scholar
Hiatt, J. F., Flloyd, T. C., Katz, P. H., et al (1985) Further evidence of abnormal Non-Rapid-Eye-Movement sleep in schizophrenia. Archives of General Psychiatry, 42, 797–802.Google Scholar
Hildebrand, J. & DeLecluse, F. (1987) Effect of ritanserin, a selective serotonin-S2 antagonist, on Parkinsonian rest tremor. Current Therapeutic Research, 41, 298–300.Google Scholar
Idizikowski, C., Mills, F. J. & Glennard, R. (1986) 5-Hydroxy-tryptamine-2-antagonist increases human slow wave sleep. Brain Research, 378, 164–168.Google Scholar
Lambert, P. A., Bouchardy, M., Marcou, G., et al (1969) Principales indications du pipampérone. Compte rendu Congrès Psychiatrique et Neurologique de Langue Francaise, LXVII e session, Bruxelles, Septembre 1969.Google Scholar
Peroutka, S. J. & Snyder, S. H. (1980) Regulation of serotonin-2 (5HT2) receptors labelled with (3H) spiroperidol by chronic treatment with the antidepressant amitriptyline. Journal of Pharmacology and Experimental Therapeutics, 215, 582–587.Google Scholar
Reyntjens, A. J. M., Gelders, Y. G., Hoppenbrouwers, M.-L. J. A., et al (1986) Thymosthenic effects of ritanserin (R 55667), a centrally acting serotonin-S2 receptor blocker. Drug Development Research, 8, 205–211.CrossRefGoogle Scholar
Riederer, P., Auff, E., Birkmayer, W., et al (1986) Ritanserin in the treatment of tremor-dominant Parkinson's disease. Proceedings of the 4th European Workshop on Clinical Pharmacology, Pamplona, June 1986.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.